Evaxion A/S (EVAX) Earnings Call Transcript
November 6, 2025
Earnings Call Speaker Segments
Hello, everyone, and welcome—whether it's morning or afternoon where you're joining from. We appreciate you taking part in this call, where we'll discuss both our business update for the third quarter of 2025 and our financial results. I'm Birgitte Rønø, and I hold the positions of Chief Scientific Officer and Interim CEO at Evaxion. Joining me are Thomas Schmidt, who is our Chief Financial Officer, and Mads Kronborg, our Vice President of Investor Relations and Communications. To begin, let me give you a quick overview of the agenda for today. First, I'll provide a brief introduction; next, I'll share an update on R&D; after that, Thomas will present the financial results for Q3; and once we've wrapped up with some closing thoughts, we'll open the floor to your questions. Before we get started, I'd like everyone to keep in mind that this presentation might include forward-looking statements, which come with risks and uncertainties, meaning the actual outcomes may differ materially. Most importantly, I'm pleased to announce that as of November 24, Dr. Tayton-Martin is joining us. She brings extensive experience in biotech leadership, raising funds, and forming partnerships. Helen is a co-founder of Adaptimmune, where she has held several senior executive roles. She holds a PhD in molecular immunology as well as an MBA, and with more than 30 years of experience covering everything from early research to product approval, Helen is the perfect person to steer Evaxion's strategy through its next phases. So that means I'm returning to the CSO position I held before. Helen is moving from her board director seat into the CEO role, and Jens Bitsch-Nørhave will come onto the board as an advisor and observer; the plan is for him to stand for election when the next AGM takes place. A number of important milestones have been reached since we last gave a business update: MSD's in-licensing of EVX-B3 — a landmark deal — delivered both meaningful cash and outside validation. The evaluation window for EVX-B2 has been lengthened. We currently have several partnership conversations in progress, even though conditions in the market are making deals harder to close; at the ESMO Congress we shared two-year clinical efficacy data on EVX-01; and EVX-04, a new therapeutic cancer vaccine aimed at acute myeloid leukemia, has been brought into our pipeline. On top of that, our AI-Immunology platform now includes an automated module for vaccine design, which raises quality while shortening how long design takes. And we've also bolstered the company's finances — thanks to a $7.5 million option exercise fee from MSD along with other sources of capital market funding, our cash runway reaches into the second half of 2027, and Thomas will walk through the specifics. As I noted, the transformative MSD deal stands out among this quarter's key highlights. September 25th became a landmark date for Evaxion, when MSD, also known as Merck, chose to exercise its option on EVX-B3. That represented the very first time a major pharma company in-licensed a vaccine candidate found through AI. To repeat what was mentioned, that $7.5 million exercise fee gives us a much longer cash runway. This deal proves our approach of creating value by working with partners—even one as large as MSD. It also serves as validation for our AI-Immunology work and our R&D pipeline, and it guarantees that EVX-B3 will move forward with no expense to Evaxion. Apart from the EVX-B3 deal itself, the evaluation window for EVX-B2 has been lengthened. For Evaxion, 2025 is looking like a defining year. We've reached several key milestones since the last time we shared a business update. To start, MSD has chosen to exercise its option for EVX-B3. In addition, we presented two-year clinical results from the phase II trial of EVX-01, and we told you that EVX-04 now sits within our pipeline. That compound is the top prospect for the precision cancer vaccine we're developing. Going forward, our aim is to provide additional news regarding research and development as well as business development. With that said, let's focus on what we've achieved lately in R&D and AI-Immunology. Our new AI-created cancer vaccine candidate goes by the name EVX-04, and it goes after non-conventional antigens that come from the dark genome, otherwise called endogenous retroviruses, or ERVs. Such ERVs are expressed only in cancers that are abundant in normal tissue, and that quality renders them an attractive target for vaccines against cancer. EVX-04 is a cancer vaccine designed as a therapy, and its goal is to bring the immune system under control in acute myeloid leukemia—a disease where, as everyone knows, relapse remains a serious problem. This vaccine is built on our AI-immunology platform, and it leverages our discovery engine to identify several ideal tumor-specific epitopes that match both the ERV expression profile and the immune features seen in patients. At this point, we've completed the design of the lead candidate and conducted preclinical work. What comes next is GMP manufacturing along with additional R&D enabling studies, all in preparation for a first-in-human trial. Now that the lead vaccine candidate for EVX-01 has been chosen, the program has been incorporated into our pipeline. We're also cutting the EVX-02 program because nothing is actively being developed for it right now. Thanks to the EVX-02 vaccine program, we were able to demonstrate proof of concept for delivering neo antigen via DNA, and the lessons learned shaped how EVX-03 and EVX-04 were designed. Turning to our lead candidate, EVX-01, it's a personalized cancer vaccine that carries several targets specific to each patient — neo antigens — which we pinpoint from the patient's tumor material through our AI-Immunology platform. To enhance clinical efficacy, EVX-01 is administered alongside pembrolizumab, an immune checkpoint inhibitor. During an oral session at the ESMO Congress in October, we shared two-year clinical outcome data from our phase II trial. The data we got back are really promising, and the science and medical communities responded positively to them. During the congress, we shared that the objective overall response came in at 75%. On top of that, among the 12 patients who responded, 11 still showed a sustained response when we checked at the two-year point. We additionally found a conversion rate of 34% — that means people whose disease had been stable or who had a partial response went on to see their response deepen once they received EVX-01. Given all this, the clinical outcome data strike us as quite encouraging, and furthermore, we think they stack up well against historical data for pembrolizumab therapy. Equally heartening is how strong EVX-01's immunological activity turned out to be, which is hugely important when it comes to efficacy over the long term. Specifically, each and every patient who received EVX-01 displayed a T-cell response specific to a neo antigen. On top of that, in looking at how each patient's immune system reacted to specific neo antigens, we found that across all the people treated, 81% of the vaccine neo antigens we gave turned out to be immunogenic. That's a very high hit rate, and it gives us solid proof that our AI-immunology platform can predict these things well. We also showed that those immune responses held up for the entire two-year length of the trial. Even after the dosing period ended, T-cell activity remained high, which tells us the immune memory is lasting. And when it comes to preventing relapses and keeping melanoma under control over the long term, having T-cell responses that endure is absolutely critical. All of this makes a stronger case for EVX-01 as a personalized immunotherapy that not only shrinks tumors when combined with a standard of care, but also builds up a strong immune defense. Like we said earlier, there's now an automated vaccine design component within our AI platform. It shortens the time needed for design quite a bit and moves development schedules along faster too. With it, we can fine-tune vaccine candidates very precisely, whether they're brand-new or already approved. Everything runs automatically these days, all the way from feeding in data to producing candidates, which guarantees the best possible sequence and conformation for vaccine targets. As we noted before, set against conventional approaches, this new component speeds vaccine work up and brings expenses down. On top of that, it connects smoothly with what happens further down the line, helping things move without friction from design into production. A number of our major R&D efforts have already made use of this design component. To start with one illustration: we used this module to pinpoint and pick out parts of an antigen capable of being expressed. Because of limits tied to solubility, we saw that expressing the antigen at full length wasn't possible. Once the new module was brought in, we found shortened versions of those antigens that could be expressed, which unlocked the door to preclinical assessment of that antigen. As another use case, the module lets us forecast the best possible sequences for a vaccine target, working from a supplied structure of an antigen protein. In this instance as well, we managed to rescue a protein that is difficult to express, one that otherwise would have demanded labor-intensive, trial-and-error design work to uncover constructs that could be expressed. This newly introduced design component put our company at the leading edge of vaccine innovation powered by AI, and it gave us added ability to accelerate all the way from identifying targets through to a finished product candidate. So to wrap up, we've made considerable headway throughout our R&D pipeline and our AI platform, and the upcoming milestones remain within reach on schedule. We're eager to share further news as our programs keep moving forward. With that said, I'd now like to hand things over to Thomas, who will walk you through the financial results.
Thank you, Birgitte. It's a pleasure to walk everyone through the quarter's financial results. Perhaps I should begin by giving a picture of what we've accomplished over the year so far, reflecting solid delivery against the financial strategy we set. As the slide shows, during this year we've carried out several capital market initiatives, including, of course, the debt conversion arrangement reached with the European Investment Bank, along with the MSD out-licensing deal for EVX-B3. So across the year and through the close of October, our activities total $31.8 million, all of which essentially reinforces our equity and, without question, our runway, now pushed out into the second half of 2027. That's genuinely a solid achievement, and it follows the financial strategy we've established. Turning to the third quarter and its highlights, we've clearly delivered a robust financial performance for the period. As I noted, the cash runway has now been lengthened into the second half of 2027. We also saw during the quarter the option exercised by Merck, or MSD, which delivers cash income today while additionally carrying potential future revenue of as much as $592 million. We remain firmly on track in the third quarter toward meeting our full-year financial targets, and over the quarter we further shored up our equity via the European Investment Bank debt conversion as well as the MSD proceeds — so a genuinely strong quarter. Looking more closely at the profit and loss side, plainly the revenue from MSD is what powers the quarterly operational gain — a first for Evaxion — yet just as importantly, our operating expenses are not merely managed well; they're in fact marginally under last year and roughly on par with the prior quarter. So, consistent with what we communicated earlier, from a cash flow standpoint we still expect to land at approximately the $14 million operating cash flow mark. Net financials for the quarter come to about $1.3 million, propelled by the debt conversion completed in July. That July debt conversion with the EIB was executed at an 89% premium to the share price at the market close on July 10th. The premium was recognized within financial income for the quarter, which lifts income for the quarter to $4.6 million. Moving to the balance sheet: as already noted, we've kept up the strong execution that has likewise strengthened our equity. At quarter-end, equity now sits at $16.6 million. Within equity there's a derivative liability with a net impact of $1.5 million. That derivative originates from our public offering in January and the investor warrants dating from that time. But in October, as I already mentioned, we saw warrant exercises totaling 2.7 million, so the derivative's net effect will be minimal by year-end, which is also a favorable result; it has additionally cut our outstanding warrants by 1 million ADSs, leaving us with 2.8 million outstanding warrants remaining. Also worth noting is that our cash balance at the end of June stands at a healthy and robust $10.6 million, and we anticipate additional cash coming in during October, the revenue income from MSD plus the cash from share sales tied to the investor warrant exercise; and finally, the debt-to-equity conversion with the European Investment Bank has genuinely bolstered our balance sheet, has enhanced our cash flow going forward, and has certainly brought our leverage down as well. So that event too was truly an excellent result; so, a strong solid quarter in line with our financial strategy. And with that, I'll now hand it back to Birgitte.
Thanks, Thomas. Now, to wrap things up, I want to point out that our operational momentum is solid. We've hit most of the milestones we set for 2025, and we're on course for a number of possible value catalysts. Business development is still a top priority, and we currently have several partnership conversations happening at the same time. Our cash runway now stretches into the second half of 2027. With that, thank you for spending your time with us and for your attention, and we'd be glad to take any questions. Kindly follow the operators' directions. Thank you.
Morning, all, and well done on the strides made during this quarter. One brief item regarding EVX-01. Could you share any details about the possible partnership arrangement, and what's the main thing a partner keeps asking you? Are they inclined to hold out for data covering a longer time frame, or some other important milestone that needs to be shown before a deal can go through? Thanks for asking that. As I mentioned, we've just shared the clinical outcome data covering 2 years; and I'd say the conversation has shifted away from concerns about data quality and how our platform operates, toward instead how your technology might be used in other kinds of cancer indications. So, the data went over well, and we've been talking it through with key opinion leaders. We've also been talking it through with potential partners. And our strategy is to out-license it at the stage of development it's at right now, and then the partner can, naturally, choose what the next steps might be. If we stay on the path we're on now with advanced melanoma, the step that would most likely come next would be running a bigger randomized control arm study comparing the combination of EVX-01 plus standard of care against standard of care by itself, so that's at minimum 1 possibility, but we also notice the potential in taking our technology and using it for other disease or cancer indications where mutational burden runs high, which means we can pick high-quality new antigens and put together a vaccine that would help the patient, so several different conversations are underway, and different questions keep reaching us too, but on the whole, the questions aren't about data quality or data impact, but rather how we can push this ahead jointly and come up with solutions for manufacturing and for other indications as well. Understood. Thanks. Appreciate that. One final item. Congrats on revealing EVX-04 in the AML program. Could you give us a bit of insight into the target, or how it gets expressed on AML stem cells? CD33 and CD123 have both been attempted, and we're trying to grasp what sets this target apart.
Yeah. No, that's a really good question; so, the approach we've taken with our AI-Immunology platform involves examining genomic and transcriptomic data. And for this specific category of antigens, what we mostly examine is transcriptomic data. So, the sequences that get expressed as messenger RNA or RNA more broadly within the tumors. So what we did first was look closely at a number of distinct novel antigen classes, and we found that for some indications — AML being one — you see extremely elevated expression of those endogenous retroviral sequences coming out of the dark genome. That means that across patients, we're able to identify sequences that are shared, insert them into a vaccine, and in that way treat multiple patients with just one vaccine. So this is an off-the-shelf strategy in which the very same vaccine can be applied across varying tumor profiles as well as across patients' differing immune characteristics. Even so, we continue to rely on AI-Immunology and our core technology to pinpoint the most optimal antigens. The only difference now is that it originates from the dark genome.
Understood. Thanks a lot, and once more, well done on the advances.
Thanks.
Hey, this is Nelson filling in for Thomas. Congratulations on everything you've accomplished during this quarter. I might start with my two questions, and I apologize in advance if I've overlooked any of this. I ran into some technical problems, but there's been plenty of news recently. Perhaps at a broad level, could you share your thoughts on the general scope of partnership discussions taking place across your pipeline and how those discussions have changed throughout the past year? Then, regarding the mix of business development talks you're currently engaged in, could you describe how many center on target discovery as opposed to the programs that are already part of your pipeline? Thank you.
Yes, hello Thomas. I appreciate the question. We currently have several conversations underway, and I'd describe the interest as spanning our R&D pipeline while also focusing on our abilities to identify novel targets, meaning traditional target discovery efforts. There's interest in our oncology programs, and infectious disease programs are drawing interest as well. It's somewhat varied, I'd say, and certain companies lean toward infectious disease. Some are interested both in vaccine candidates we've created and in collaborations around target discovery, so it's a bit of a mix, and that, I'd say, validates our approach of monetizing both our internally developed vaccine candidates and by pursuing target discovery collaborations. I'm not able to say much about precisely where things stand, since it's genuinely hard to predict exactly when these various conversations might turn into an actual deal. But there's a great deal of activity, and we notice interest growing whenever major data readouts occur, as happened during this past quarter when the EVX-01 phase II data was released.
Great. Appreciate you taking our questions.
Thank you very much. This is RK calling from H.C. Wainwright. Good afternoon, Birgitte, and to the whole team.
Hello.
There are definitely some quite compelling things happening at the company right now. Let's zoom in for a moment on your automated design module, which is another intriguing AI-driven drug design tool that you have. How should we be thinking about it? Could it only assist with your in-house design work — meaning designing molecules for your own pipeline — or might it be opened up for partnerships, or even used in a separate licensing arrangement where one of your partners could bring it into their own computing environment and apply it to their proprietary molecules? It seems like there are many possible paths for this. What's your view on that?
Yes, that's exactly right. There are several directions this could take; historically, we've relied on AI-Immunology to pinpoint novel vaccine targets. Those targets were subsequently handled through manual steps, making sure we could express them as well as manufacture them. That workflow required a lot of labor. So the goal became establishing an automated approach for it. We've now managed to introduce a new module in which multiple distinct AI tools are combined, letting us move from discovering a target all the way to selecting a product candidate extremely quickly. Naturally, that can be used for our own programs, but we also see a possibility of leveraging this capability to help other companies make certain that whatever they choose as their key antigens or, more broadly, key targets, those antigens or targets can likewise be generated in a cost-effective manner; so I do see several ways to monetize this new module.
All right. So moving on to practical matters, let's spend another minute on EVX-01. You plan to share further data from the trial that's still running at ESMO. What kind of data is likely to emerge there, and in what way would it bolster your story around EVX-01, both for your own purposes and for a possible partner — whether that's regarding just the drug or the platform, as you mentioned while you were responding, Soumit Roy?
Yes. So we presented the clinical outcome data at ESMO, and we're still analyzing patient samples. We've gathered blood samples prior to therapy, while vaccination was underway, and then follow-up samples as well. All those patient samples are right now being evaluated in our own laboratory. So naturally we monitor the T-cell responses induced by EVX-01, but we're also doing a more thorough phenotypic analysis. Some of this is going to be shared at SITC. We have a poster presentation there, and at upcoming conferences too, since we haven't yet analyzed all the numerous samples taken from the patients, so there's more to come, further deep dives into the immune profiles of cells gathered from the patients, and beyond that we have the extension phase of the EVX-01 trial, in which six patients are now getting EVX-01 as a monotherapy, so additional data will emerge from this subset of patients.
Great. Thanks for that. My final question concerns the MSD partnership. Getting the $7.5 million is wonderful, but what additional amount is still required before you can supply further data on the second molecule? Or does Merck still need to finish its due diligence on the data you are handing over — running confirmatory studies or analyses of that data — before deciding whether to commit the remaining $2.5 million?
Yes. Regarding EVX-B2, MSD right now is reviewing the data we supplied, and beyond that, they are working on generating confirmatory analysis. That is also the reason the evaluation period got extended, so we anticipate an answer from them in the second half or the first half of next year. Great. The process continues, and naturally it is very exciting, and out-licensing EVX-B2 to MSD would be something we would love.
Yes. All right. Excellent. I appreciate it. I'm very grateful that you accepted every one of my questions.
You're welcome.
Absolutely, and we appreciate you being with us on this call. If anything else comes to mind, feel free to get in touch. Thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Evaxion A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Evaxion A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.